Buy, Sell, Hold: stocks are being tracked by analysts today
Godrej
Properties
Brokerage: Macquarie | Rating: Downgrade to Neutral |
Target: Rs 650
The global research firm said that RERA & GST will yield
market-share gains in the medium term. Further, it said that it liked the
company’s strategy to add new projects to its portfolio through attractive
deals. Currently, it believes that Phoenix Mills offers better risk/reward in
the sector.
Brokerage: CLSA | Rating: Buy | Target: Rs 873
CLSA said that Q2 earnings growth of 88% YoY was above
estimates. Further, it added that BKC office space sale drove the revenue
surprise. Further, strong pre-sales momentum should continue and it increased
the earnings to reflect a likely record year.
Titan
Brokerage: Macquarie | Rating: Outperform | Target: Raised
to Rs 907
The brokerage raised FY17-20 earnings estimate by 17-18%
owing to higher jewellery sales. It also believes higher valuation will sustain
on potential market share gains.
Brokerage: Credit Suisse | Rating: Outperform | Target:
Raised to Rs 760
Credit Suisse said that the results were a massive beat on
margin and the momentum on market share gain continues. There was a big
surprise on jewellery segment margin which are up 260 basis points.
Brokerage: Morgan Stanley | Rating: Overweight | Target:
Rs 920
The brokerage house said that Q2 margin expansion is likely
to be sustained. It sees 40% upside from current levels.
Hindalco
Brokerage: Credit Suisse | Rating: Outperform | Target:
Raised to Rs 310
Credit Suisse observed that the company’s Q2 standalone
earnings were in-line with estimates. Further, it increased Novelis FY18 EBITDA
& slightly increased volume for domestic operations. It also raised EPS
estimates due to cash settlement in Q2 Novelis-Kobe JV.
Torrent Pharma
Brokerage: Credit Suisse | Rating: Outperform | Target:
Raised to Rs 1,600
The global research firm said that synergy guidance from
Unichem’s acquisition is 2x expectations. Further, it also said that the deal
catapults company to rank 2 in the cardiac segment. It cut FY18/19 EPS to
14%/28% as it build in deal with Unichem.
Brokerage: Nomura | Rating: Buy | Target: Rs 1,396
The brokerage said that Unichem acquisition is a good deal,
but said that it could be earnings-dilutive initially. But it could be
value-accretive as well, it added. Margin of the acquired business can expand
to 30-40% from 20%.
Capital Ways Financial Services
605, Industry House , AB road Indore (MP) 452001
7771800797, 8517810864
Share story
0 comments: